Transarterial chemoembolization as an alternative to radioembolization is associated with earlier tumor recurrence than in radioembolization-eligible patients.

Front Oncol · 2023 · PMC10013818 · PMID 36925930

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

The risk of death was 35%–92% higher in the TARE-ineligible group than the TARE-eligible group, although it failed to reach statistical significance in multivariable and/or IPTW analyses.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.